USA flag logo/image

An Official Website of the United States Government

Rapid, accurate and user-friendly clinical surge-testing for biothreat agents

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65979
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI055195
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
FIRST LIGHT BIOSCIENCES, INC.
1 OAK PARK DR BEDFORD, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Rapid, accurate and user-friendly clinical surge-testing for biothreat agents
Agency: HHS
Contract: 2R44AI055195-06
Award Amount: $2,992,554.00
 

Abstract:

DESCRIPTION (provided by applicant): Following a major bioterrorism attack or infectious disease outbreak, millions of potential victims may require rapid testing to ensure delivery of life-saving therapeutic treatment to those who need it. Because today t here is no diagnostic method capable of high-performance large-scale testing in a crisis situation, thousands could die needlessly due to inefficient targeting of precious medical resources. We are developing the MultiPathTM Surge Testing Platform, the fir st high-performance high-throughput system designed for on-site clinical surge testing. The MultiPath system is an ideal surge-testing platform, being rapid, high throughput, sensitive, quantitative, accurate, cost-effective, user-friendly, portable, and a utomated. It accommodates tests for a broad menu of biothreat or infectious disease agents including bacteria, fungi, viruses, and toxins. While as sensitive as high performance central laboratory tests, the MultiPath assays are as rapid and as easy-to-use as over-the-counter rapid tests and require no sample preparation. The proprietary MultiPath immunoassay technology achieves high sensitivity and quantification by using digital imaging to count target molecules tagged with fluorescent particles without u sing magnification. The MultiPath assay design eliminates wash steps, reducing engineering complexity and cost while increasing throughput. Under a Phase II SBIR we designed and integrated a fully functional prototype of the MultiPath Surge Testing Platfor m and a sensitive surge test for anthrax. Our data demonstrate that the MultiPath Anthrax test rapidly (6 min) and sensitively (low pg/ml) detects two anthrax markers with high accuracy (internal positive and negative control assays are included for each m arker) and specificity in small whole blood fingerstick samples with no sample prep. The prototype MultiPath platform automatically performs 600 assays/hour and integrates automated liquid handling, sample tracking, data analysis, and report generation. We propose to develop the commercial MultiPath Surge Testing Platform and MultiPath Anthrax Test. Specifically, we propose to (1) develop commercial quality particle-based immunoreagents for the ultra-sensitive MultiPath Anthrax test, (2) develop manufacturi ng procedures for large scale production of reagents that can be stored long-term at room temperature, (3) develop the commercial MultiPath Surge Testing Platform, (4) integrate the MultiPath Surge Testing Platform and MultiPath Anthrax test, and (5) verif y the efficacy of the platform and anthrax test. To supplement our core expertise in developing MultiPath platform and assays, we will leverage the expertise of academic, industry, and government collaborators. On completion of the proposed project we will begin validation of the platform and anthrax test for subsequent regulatory submission. We propose to deploy the surge-testing platform and reagents to test for a menu of biothreat and disease outbreak agents at key points in the public health system - in cluding the Strategic National Stockpile, state and city public health institutions, and the Laboratory Response Network. PUBLIC HEALTH RELEVANCE: Following a major bioterrorism attack or infectious disease outbreak, millions of potential victims may requi re rapid and efficient testing to ensure delivery of life-saving therapeutic treatment to those who need it. Because today there is no diagnostic method capable of high-performance large-scale testing in a crisis situation, thousands could die needlessly d ue to inefficient targeting of precious medical resources. To address the critical gap in the nation's public health preparedness for large-scale surge testing we propose to develop the MultiPath Surge Testing Platform and the MultiPath Anthrax Test.

Principal Investigator:

Sadanand Gite
6172306440
SADANAND@FIRSTLIGHTBIO.COM

Business Contact:

Sadanand Gite
sadanand@firstlightbio.com
Small Business Information at Submission:

FIRST LIGHT BIOSCIENCES, INC.
FIRST LIGHT BIOSCIENCES, INC. 1 OAK PARK DR BEDFORD, MA 01730

EIN/Tax ID: 120812181
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No